The Addario Lung Cancer Medical Institute (ALCMI) is a 501(c)(3) non-profit, public charity organization, with offices in California and Connecticut and member institutions in the US and Europe, dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. In response to widely-acknowledged and systematic barriers to progress against lung cancer, ALCMI developed and launched, as its inaugural research program, a targeted, multi-institutional biorepository. The purpose of this project is to facilitate application of the known biomarkers to patients presenting today, and to establish such a collection of biospecimens that will be essential for discovering and validating new biomarkers for improved diagnostics, treatments and cancer patient outcomes.

ALCMI in Amsterdam. 2011 World Conference on Lung Cancer.

The Addario Lung Cancer Medical Institute (ALCMI) held a Satellite Symposium at the 14th World Conference on Lung Cancer on Sunday, 3 July 2011 in Amsterdam Rai, The Netherlands. The title of the symposium is “The Way Forward for Molecular Diagnosis and Treatment in Lung Cancer.”